Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | GPX4 | P36969 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21177650 | 0.90 | LMNA (0.39) | LMNACYP2C9KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL27299791 | 0.77 | ALDH1A1 (0.38) | KMT2ASMN1; SMN2ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL21177572 | 0.75 | SMN1; SMN2 (0.42) | LMNACYP2C9KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL31160508 | 0.74 | CHRNB2 (0.41) | KMT2ASMN1; SMN2ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL28976097 | 0.69 | ITK (0.39) | KMT2ARAB9AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL28552139 | 0.69 | ALDH1A1 (0.77) | KMT2ASMN1; SMN2ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL19017644 | 0.69 | ALDH1A1 (0.43) | KMT2ASMN1; SMN2ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12583398 | 0.67 | CA2 (0.45) | CA2CA12CA1CA9CHKA | |
| SCHEMBL9396214 | 0.67 | CA2 (0.59) | CA2CA12CA1CA9CHKA | |
| SCHEMBL20551511 | 0.67 | CYP2C9 (0.55) | LMNACYP2C9KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902403-B | Substituted alkynylene compounds as anticancer agents | 奥里吉恩发现科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | AURIGENE ONCOLOGY LTD (IN) | 2023-07-06 | — | — | US | disclosed |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | AURIGENE ONCOLOGY LIMITED (IN) | 2023-04-25 | — | — | US | disclosed |
| CN-111902403-A | Substituted alkynylene compounds as anticancer agents | 奥里吉恩发现科技有限公司 | 2020-11-06 | — | — | CN | disclosed |
| WO-2019142126-A1 | SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210847-A1 | Substituted Alkynylene Compounds As Anticancer Agents | MCL1, ROS1, MKI67 | LMNA 1512/4885CYP2C9 3082/4885KMT2A 2821/4885 |
| US-11633394-B2 | Substituted alkynylene compounds as anticancer agents | MCL1, ROS1, MKI67 | LMNA 1512/4885CYP2C9 3082/4885KMT2A 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.